Pharmacologic therapy for the cancer anorexia/weight loss syndrome: A data-driven, practical approach

Journal of Supportive Oncology

Volumn 4, Issue 10, 2006, Pages 499-502

  Jatoi, Aminah ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; APPETITE STIMULANT; CORTICOSTEROID; CREATINE; DEXAMETHASONE; DOCETAXEL; DRONABINOL; FLUOXYMESTERONE; GESTAGEN; GHRELIN; HYDRAZINE SULFATE; ICOSAPENTAENOIC ACID; MEGACE ES; MEGESTROL; MELATONIN; OXANDROLONE; PENTOXIFYLLINE; PLACEBO; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ADRENAL SUPPRESSION; ADVANCED CANCER; ANOREXIA; BODY WEIGHT DISORDER; CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; DIET THERAPY; DISEASE ASSOCIATION; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG INDICATION; DRUG WITHDRAWAL; EARLY INTERVENTION; ENTERIC FEEDING; FAMILY COUNSELING; HUMAN; HYPOPHYSIS ADRENAL SYSTEM; IMPOTENCE; INCIDENCE; MENSTRUATION; MYOPATHY; NUTRITIONAL COUNSELING; PARENTERAL NUTRITION; PATIENT EDUCATION; PROGNOSIS; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; SYSTEMATIC REVIEW; THROMBOPHLEBITIS; WEIGHT REDUCTION;

ANOREXIA; ANTINEOPLASTIC AGENTS; APPETITE; APPETITE STIMULANTS; BODY WEIGHT; HUMANS; NEOPLASMS; NUTRITIONAL SUPPORT; QUALITY OF LIFE; WEIGHT LOSS;

EID: 33846303191     PISSN: 15446794     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Sarhill N, Mahmoud F, Walsh D, et al. Evaluation of nutritional status in advanced metastatic cancer. Support Care Cancer 2003;11:652-659.
2. Tramner JE, Heyland D, Dudgeon D, et al. Measuring the symptom experience of seriously ill cancer and noncancer hospitalized patients near the end of life with the memorial symptom assessment scale. J Pain Symptom Manage 2003;25:420-429.
3. Armstrong L, Jenkins S. It's Not About the Bike: My Journey Back to Life. New York: G. P. Putnam's Sons; 2000.
4. Dewys WD, Begg C, Lavin PT, et al. Prognostic effect of weight loss prior to chemotherapy in cancer patients. Eastern Cooperative Oncology Group. Am J Med 1980;69:491-497.
5. Tamburini M, Brunelli C, Rosso S, Ventafridda V. Prognostic value of quality of life scores in terminal cancer patients. J Pain Symptom Manage 1996;11:32-41.
6. Moertel CG, Schutt AJ, Reitemeier RJ, Hahn RG. Corticosteroid therapy of preterminal gastrointestinal cancer. Cancer 1974;33:1607-1609.
7. Loprinzi CL, Kugler JW, Sloan J, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/cachexia. J Clin Oncol 1999;17:3299-3306.
8. Jatoi A, Kumar S, Sloan JA, Nguyen PL. On appetite and its loss. J Clin Oncol 2003;21(9 suppl):79-81.
9. Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990;82:1127-1132.
10. Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993;11:762-767.
11. Geels P, Eisenhauer E, Bezjak A, Zee B, Day A. Palliative effect of chemotherapy: objective tumor response is associated with symptom improvement in patients with metastatic breast cancer. J Clin Oncol 2000;18:2395-2405.
12. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-2103.
13. Jatoi A, Windschitl HE, Loprinzi CL, et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia. J Clin Oncol 2002;20:567-573.
14. Goldberg RM, Loprinzi CL, Mailliard JA, et al. Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double blind, placebo-controlled trial. J Clin Oncol 1995;13:2856-2859.
15. Jatoi A, Rowland K, Loprinzi CL, et al. An eicosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting. J Clin Oncol 2004;22:2469-2476.
16. Loprinzi CL, Goldberg RM, Su JO, et al. Placebo-controlled trial of hydrazine sulfate in patients with newly diagnosed non-small cell lung cancer. J Clin Oncol 1994;12:1126-1129.
17. Kardinal CG, Loprinzi CL, Schaid DJ, et al. A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 1990;65:2657-2662.
18. Joque L, Jatoi A. Total parenteral nutrition in cancer patients: why and when? Nutr Clin Care 2005;8:89-92.
19. Jatoi A, Foster N, Johnson P, et al. Investigating four 'myths' surrounding dysphagia in patients with metastatic esophageal cancer: a multi-institutional study from the North Central Cancer Treatment Group. Dis Esophagus 2004;17:292-296.
20. Rowland KM, Loprinzi CL, Shaw EG, et al. Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. J Clin Oncol 1996;14:135-141.
21. Ravasco P, Monteiro-Grillo I, Vidal PM, Camilo ME. Dietary counseling improves patient outcomes: a prospective, randomized, controlled trial in colorectal cancer patients undergoing radiotherapy. J Clin Oncol 2005;23:1431-1438.